AKTS · CIK 0002035832
Aktis Oncology, Inc.
What Aktis Oncology, Inc. owns has not been researched yet. This page is its ownership register, who holds it, and the absence of holdings below means nobody has looked rather than that there is nothing to find.
Aktis Oncology, Inc. - Profile
- Industry
- Pharmaceutical PreparationsSIC 2834
- Listed on
- Nasdaq
- Employees
- 79stated 2025
- Incorporated in
- Delaware
- Financial year ends
- 31 December
Source
Address, industry classification, listing and incorporation come from Aktis Oncology, Inc.'s own SEC filer record, so the industry is the SEC's dry classification rather than a marketing label. The headcount is the figure the sources below state for 2025. The description was written for this site in August 2026 from Aktis Oncology, Inc. Form 10-K for fiscal year 2025, Aktis Oncology, Inc. Form 10-Q for the quarter ended 30 June 2026 and Aktis Oncology, Inc. Form 8-K dated 13 August 2026, Exhibit 99.1 (second quarter 2026 results), not taken from any single article.
Share price
AKTS
Description
Aktis Oncology, Inc. is a clinical-stage oncology company in Boston, Massachusetts that develops targeted radiopharmaceuticals on a proprietary miniprotein radioconjugate platform. Its miniproteins are designed to bind tumor-surface targets and deliver the alpha-emitting radioisotope actinium-225, with rapid clearance from normal tissues to limit systemic radiation exposure. Lead candidate [225Ac]Ac-AKY-1189 targets Nectin-4 and is enrolling in the Phase 1b NECTINIUM-2 trial in locally advanced or metastatic urothelial cancer, with preliminary data expected in the first quarter of 2027. Second candidate [225Ac]Ac-AKY-2519 targets B7-H3: its INDs were cleared by the FDA in March 2026, and the Phase 1b BActinium-1 trial in metastatic castration-resistant prostate cancer was enrolling as of August 2026. Its only partnership is a May 2024 discovery collaboration with Eli Lilly and Company covering separate targets: $60.0 million upfront, up to $525.0 million in development and launch milestones, up to $630.0 million in sales milestones, and a concurrent $10.0 million purchase of Series A-1 preferred stock by Lilly. Net loss was $63.7 million in 2025 and $42.5 million in the first half of 2026, against $6.6 million of collaboration revenue in that half. Cash and marketable securities were $517.3 million at 30 June 2026. Aktis had 79 full-time employees at 31 December 2025.
Who owns Aktis Oncology, Inc..
Nothing recorded on this side. That is a sourced finding rather than a gap where the research notes say so: see the notes below.
Select a row or a slice for its provenance: the filing it came from, when it was measured, and the arithmetic behind it if it was modelled.
The full register, from 13F filings
The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 66 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.
66 managers reported a position, together holding 35.2m shares. The 40 largest are listed.
Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.
What a reader needs to know to read these numbers
- Added 27 Aug 2026 by scripts/promote_discovered.py. This company reached the site because a covered investor holds it, not because an index listed it: it was a position in a portfolio here with no page of its own. The match was proved by requiring the register built for this CIK to contain the same CUSIP the portfolio held.
- Discovered at CUSIP 01021M104, held by ameriprise, bank-of-america, blackrock, bny-mellon, citigroup, fidelity-fmr, fifth-third, geode, goldman-sachs, invesco, jpmorgan, merck, metlife, morgan-stanley, northern-trust, pnc, raymond-james, state-street, vanguard, wells-fargo.
- Holdings are NOT researched. The empty holdings list means nobody has looked at what this company owns, not that it owns nothing, and the page says so.
- Shares outstanding and market cap are null rather than guessed. Neither was captured on the dated sweep that carries every other company here.
Looked for, not found
Recorded rather than filled in. Each of these is a place where a number could have been invented and was not.
- Shares outstanding.
- Market capitalisation.